Statement from the CEO

During 2017, the number of newly registered drugs increased compared to 2016. Cancer was the disease against which most new drugs were targeted. Kancera contributed  to the development of one of these, Enasidenib, by identifying the basic chemical substance on which the drug is based1. Enasidenib is used to treat acute myeloid leukemia (AML).

In the field of inflammation, the presentation of the results from Novartis’ so-called CANTOS study (Canakinumab2 Anti-inflammatory Thrombosis Outcomes Study) was one of the major events in 2017.

The study showed for the first time convincing clinical evidence that anti-inflammatory treatment reduces the risk of complications following myocardial infarction. In addition, the follow-up analysis of the study showed a surprisingly strong and dose-dependent decrease in lung cancer in patients treated with Novartis anti-inflammatory drug.

The findings of the CANTOS study thus also support the further development of Kancera’s KAND567, which in a new way controls

During 2017, the number of newly registered drugs increased compared to 2016. Cancer was the disease against which most new drugs were targeted. Kancera contributed  to the development of one of these, Enasidenib, by identifying the basic chemical substance on which the drug is based1. Enasidenib is used to treat acute myeloid leukemia (AML).

In the field of inflammation, the presentation of the results from Novartis’ so-called CANTOS study (Canakinumab2 Anti-inflammatory Thrombosis Outcomes Study) was one of the major events in 2017.

The study showed for the first time convincing clinical evidence that anti-inflammatory treatment reduces the risk of complications following myocardial infarction. In addition, the follow-up analysis of the study showed a surprisingly strong and dose-dependent decrease in lung cancer in patients treated with Novartis anti-inflammatory drug.

The findings of the CANTOS study thus also support the further development of Kancera’s KAND567, which in a new way controls the immune system. Kancera’s choice to develop KAND567 against cancer and cardiovascular inflammation is further supported by both our own and independent researchers’ results in disease models and studies of human biomarkers. The goal of this development is to slow down the aggressive development of some forms of lymphoma (a form of blood cancer) and reduce cardiovascular injury after infarction.

In the recently completed Phase I clinical trial in the Fractalkine project, the results show that KAND567 blocks the Fractalkine system as hoped and the drug candidate is well tolerated in doses up to five to ten times above the calculated effective dose.

We will now continue to deepen our understanding of how KAND567 affects the liver in relation to the desired pharmacological effects in order to develop a clinical development plan for both chronic and acute treatment of inflammatory diseases and cancer. The fact that there is support for the benefit of short-term treatment with KAND567 against, for example, myocardial infarction, gives the project additional opportunities with the good safety margin we have seen in acute treatment.

As Kancera’s main resources were dedicated to the Fractalkine project in 2017, the progress of our other pharmaceutical projects have slowed down slightly. However, studies are ongoing to identify the company’s next drug candidate for clinical development in the ROR, PFKFB3 and HDAC6 projects.

February 2018
Thomas Olin

CEO Kancera AB (publ)

  1. Kancera has been fully paid for the company’s contribution to the development of Enasidenib. Enasidenib is owned by American Agios and Celgene.
  2. Canakinumab is an antibody to IL1beta.